Agent Capital Awarded “Partner of the Year” by Penn Center for Innovation, University of Pennsylvania

December 4, 2025

• Agent Capital honored for its translational impact in catalyzing commercialization of Penn-origin science at PCI’s 2025 Celebration of Innovation
• Recognition of Agent Capital’s leadership in healthcare investment, as a female-led firm advancing breakthrough therapeutics across rare disease, oncology, neurology, and immunology.
• Strong validation of Agent Capital’s strategic partnerships with academia, venture capital, and co-investors to de-risk early innovation and bring advances to patients

WALTHAM, MA — December 4, 2025 — Agent Capital, a leading healthcare and life‑sciences venture capital firm, has been awarded the Paul. D. Sehnert Memorial ‘Partner of the Year’ Award by the Penn Center for Innovation (PCI) at the University of Pennsylvania’s 2025 Celebration of Innovation (a prominent US Ivy League Institution).

The award recognizes Agent Capital’s role in identifying and funding Penn-originated therapeutic innovation, accelerating the path from academic discovery to clinical development and patient impact.

Agent Capital Founder and Managing Partner, Geeta Vemuri said “We are honored to receive this award. At Agent Capital, we are building an investment institution designed for durability and impact – one that advances transformative therapeutics built on groundbreaking science, addresses significant unmet patient needs, and allocates capital with precision and efficiency to accelerate responsible innovation and patient outcomes.”

“Agent Capital has become a trusted investor for exceptional science emerging from leading institutions,” added Carter Caldwell, Penn Medicine Co-Investment Program Director. “Their technical expertise and trusted industry connections provide what it takes to scale breakthroughs responsibly and rapidly.”

Ipsen Pharmaceuticals, one of Agent Capital’s early backers, also highlighted the firm’s durable investment strategy. “When syndicate investors look for conviction partners who pressure‑test the biology, regulatory path, commercial unmet need, and scaling milestones, Agent Capital has proven to be that rare combination,” noted Philippe Lopes-Fernandes, Chief Business Officer of Ipsen.

“This award confirms their ability to bridge complex science into de-risked patient opportunities with capital discipline” added Steven Kim, an early backer of Agent Capital and Partner at Verdis Investment Management, a prominent family office from Pennsylvania.

– ENDS –

Enquiries

Agent Capital
Julie Gionfriddo, Head of Investor Relations
info@agentcapital.com

Vigo Consulting (Media Relations)
Rozi Morris
Rozi.morris@vigoconsulting.com
+44 (0)20 7390 0231

About Agent Capital
Agent Capital is a healthcare and life‑sciences venture capital firm investing in differentiated therapeutics from preclinical through commercial scaling. The firm focuses on rare diseases, oncology, neurology, immunology, and emerging therapeutic modalities.

About the Penn Center for Innovation (PCI)
Penn Center for Innovation (PCI) is the University of Pennsylvania’s technology commercialization hub, advancing innovation through licensing, startup creation, alliance partnerships, and translational research syndication, bridging academic discovery with the private sector for meaningful societal and patient impact.

About Verdis
Verdis Investment Management, LLC (“Verdis”) is a single-family office investing globally from our base outside of Philadelphia. Verdis was established in 2004, building on a rich legacy from a family that has spanned three centuries. The views expressed above solely reflect the opinion of Verdis as of the date of publication. Verdis is registered as an investment adviser with the U.S. Securities and Exchange Commission. Registration of an investment adviser does not imply any level of skill or training. For additional information regarding Verdis, please see Verdis’ Form ADV which can be found on the SEC’s web site (www.sec.gov).